Device and delivery

flutiform provides patients with a modern yet familiar device

When treating asthma, choosing the right inhaler is important.4 Handling and inhalation errors may reduce the delivery of the treatment to the lungs,4,5 and may contribute to suboptimal control.6 Selecting a device that the patient prefers (because it’s easy to use, for example) may improve asthma control.4

Convenient and familiar

The flutiform inhaler offers your patients a range of benefits:

  • Convenience: modern, compact device with a colour-coded dose counter to help monitor doses, which may aid adherence
  • Ease of use: 99% of patients could be trained to use the flutiform device within 15 minutes, completing all 8 steps correctly (n=307)1†
  • Familiarity: delivered in the same device type as 93% of all prescriptions for SABA reliever medication7


Randomised, open-label crossover study. Participants completed all 8 pre-specified steps within 15 minutes. 

††Based on usage for all respiratory indications in France, Germany, Italy, Spain and the UK, 2015.

SABA: Short-acting Beta-agonist.

flutiform delivers the therapy to where it’s needed

Particle size and force can affect the delivery of inhaled therapy to the lungs.

Fast, forceful plumes may impact the back of the throat.10 In vitro, flutiform has a slower, less forceful plume than fluticasone propionate/salmeterol pMDI.11

flutiform - dose delivery throughout the lungs

flutiform delivers a total modelled lung deposition of up to 44% of labelled dose (estimated by Functional Respiratory Imaging), with deposition throughout central and peripheral airways (in vitro studies).3

Peripheral: Airway diameter <1–2 mm (after ~9th generation of bronchioles). 3D airway models of the lungs were created from CT scans in 6 asthma patients treated with an ICS/LABA combination therapy.

ICS: Inhaled Corticosteroid; LABA: Long-acting Beta-agonist. 

Error bars represent arithmetic standard deviations.

In vitro, flutiform delivers a high and consistent fine particle fraction of around 40% across two different inspiratory flow rates of 28.3 L/min and 60.0 L/min.12





Fine particle (<5 μm) fraction was calculated as a percentage of the metered dose strength. *Pressurised metered-dose inhaler. **Dry powder inhaler. Data shown for LABA component only.

1. Bell D et al. Respirology. 2014; 19 (Suppl. 3): 1–62, O-A-016. 2. Bell D et al. Respiratory Drug Delivery Europe. 2015; 2: 239–244. 3. Van Holsbeke C et al. Poster Presentation P910. ERS 2014. 4. Chrystyn H and Price D. Prim Care Respir J. 2009; 18: 243–249. 5. Virchow JC et al. Respir Med. 2008; 102: 10–19. 6. Papi A et al. Eur Respir J 2011; 37(5): 982–985. 7. Data on File. DOF-RESP-10011. Mundipharma International Ltd. 2016. 8. Newman SP. Chest. 1985; 88: 152S–160S. 9. Mitchell JP and Nagel MW. KONA. 2004; 22: 32–65. 10. Bell J and Newman S. Expert Opin Pulm Drug Deliv. 2007; 4: 215–234. 11. Johal B et al. Adv Ther. 2015; 32(6): 567–579. 12. Johal B et al. Comb Prod Ther. 2013; 3: 39–51.

You are now leaving and moving to an external website independently operated and not managed by Mundipharma International Ltd. Mundipharma International Ltd assumes no responsibility for the site or its content.

If you do not wish to leave this site, click Cancel or click OK to continue.

OK Cancel